← Eichor
Condition: Resistant Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Resistant Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · 18 location(s) · Pathos AI, Inc. · NCT06785636Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT06828263Intestinal Akkermansia Muciniphila in Prostate Cancer
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06242509Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administ
Phase 1/Phase 2 · 8 location(s) · SNIPR Biome Aps. · NCT06938867Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT05919329Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07443943PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06347068Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
NA · 1 location(s) · Royal Marsden NHS Foundation Trust · NCT07673861High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Phase 2 · 17 location(s) · VA Office of Research and Development · NCT05011383A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT06632860Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/Phase 2 · 1 location(s) · University College, London · NCT07414940Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome
NA · 1 location(s) · McGill University · NCT06155708Working Out M0 Bipolar Androgen Therapy
Phase 2 · 12 location(s) · Australian and New Zealand Urogenital and Prostate Cancer Tr · NCT06594926Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Phase N/A · 2 location(s) · Santa Chiara Hospital · NCT06783127ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Pros
Phase 2 · 15 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT07717268GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
NA · 1 location(s) · Sir Mortimer B. Davis - Jewish General Hospital · NCT02333110
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.